IGF2BP3 and neoplasm: IGF2BP3 as a prognostic biomarker should be further validated especially in patients diagnosed at Stage I. Furthermore, siRNA knockdown experiments using OCCC cell lines demonstrated a variety of in vitro and in vivo parameters indicating the down-regulation of MMPs, supporting a role of IGF2BP3 in tumor progression as a potential oncogenic agent.